• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

CGRP Inhibitors: A Promising New Class of Drugs for Migraine

Podcast

This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.

In May, the FDA approved erenumab, the first calcitonin gene-related peptide (CGRP) inhibitor for the prevention of migraine in adults. Since then, 2 other CGRP inhibitors have gained approval, providing a new class of drugs for those who suffer from migraine.

This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss the emerging therapy for the condition, which affects 39 million people in the United States.

Log in to listen to the podcast.

Listen above or through one of these podcast services:

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Read more:

FDA Approves Erenumab, First CGRP Inhibitor for Prevention of Migraine

Erenumab for Migraine Is Cost-Effective, but Long-Term Harms Remain Unclear

ICER Releases Final Evidence Report on Efficacy, Cost Effectiveness of CGRP Inhibitors for Migraine

Migraine Survey Highlights Significant Lack of Awareness of CGRP Inhibitors

CGRP Inhibitor Erenumab Shows Efficacy in Migraine Within 1 Week

Related Videos
Eneline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA
David Yeomans, PhD
David Yeomans, PhD
David Yeomans, PhD
David Yeomans, PhD
All of the panelists for this series
An image of all of the participants
An image of all of the participants
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.